Supernus PharmaceuticalsLTS:0LB2 +1.26%88 Days Payable is 25.06 as of Mar. 2026, which is 49% below its 10-year median of 49.12. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $40.33 (Modestly Overvalued). Among 920 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 88.04% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LB2 vs BCRX, PBH, RGC: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Supernus Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a Days Payable of 25.06 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Supernus Pharmaceuticals and its competitors. This is 49% below median its historical median of 49.12. Over the past decade, Supernus Pharmaceuticals' Days Payable has ranged from 15.35 to 188.33. According to the industry distribution chart, Supernus Pharmaceuticals ranks #810 out of 920 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is Supernus Pharmaceuticals' Days Payable too high?
Supernus Pharmaceuticals' current Days Payable of 25.06 is 49% below median its 10-year median of 49.12. Over the past 10 years, this metric has ranged from a low of 15.35 to a high of 188.33. The Drug Manufacturers industry median Days Payable is 90.84. Supernus Pharmaceuticals' value of 25.06 is 72.4% below this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #810 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Days Payable compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #810 out of 920 companies for Days Payable. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 90.84. Supernus Pharmaceuticals' value of 25.06 is 72.4% below this benchmark. Historically, Supernus Pharmaceuticals' own Days Payable has ranged from 15.35 to 188.33 over the past decade. While the company's 10-year median is 49.12 vs. the industry median of 90.84, Supernus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Days Payable of 25.06 is 72.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Days Payable is 25.06, which is 49% below median its own 10-year median of 49.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.33, compared to a current price of $46.51 — trading 15.3% above its estimated fair value. The current Days Payable is 25.06, which is 49% below median its 10-year median of 49.12 and 72.4% below the Drug Manufacturers industry median of 90.84. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Days Payable is 25.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $46.51 is trading 15.3% above its estimated GF Value™ of $40.33.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Days Payable: 25.06 (49% below median its 10-year median of 49.12)
GF Value™: $40.33 vs. price of $46.51 (15.3% above fair value)
Industry Position: 72.4% below the Drug Manufacturers median (#810 of 920)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
